Status:

COMPLETED

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Lead Sponsor:

Amgen

Conditions:

Psoriatic Arthritis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis. Apremilast is proposed to improve signs and symptoms of psori...

Detailed Description

Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in 6-39% of psoriasis patients. The immunopathogenesis of PsA, which mirrors but is not identical to that seen in psoriatic plaques, ...

Eligibility Criteria

Inclusion

  • Males or females, aged ≥ 18 years at time of consent.
  • Have a diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 6 months duration.
  • Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) PsA at time of screening.
  • Must have been inadequately treated by disease-modifying antirheumatic drugs (DMARDs)
  • May not have axial involvement alone
  • Concurrent Treatment allowed with methotrexate, leflunomide, or sulfasalazine
  • Have ≥ 3 swollen AND ≥ 3 tender joints.
  • Males \& Females must use contraception
  • Stable dose of nonsteroidal anti-inflammatory drugs (NSAIDs), narcotics and low dose oral corticosteroids allowed.

Exclusion

  • Pregnant or breast feeding.
  • History of allergy to any component of the investigational product.
  • Hepatitis B surface antigen and/or Hepatitis C antibody positive at screening.
  • Therapeutic failure on \> 3 agents for PsA or \> 1 biologic tumor necrosis factor (TNF) blocker

Key Trial Info

Start Date :

September 27 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 25 2017

Estimated Enrollment :

488 Patients enrolled

Trial Details

Trial ID

NCT01212757

Start Date

September 27 2010

End Date

January 25 2017

Last Update

May 6 2020

Active Locations (98)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 25 (98 locations)

1

Clinical and Translational Research Center of Alabama, PC

Tuscaloosa, Alabama, United States, 35406

2

Denver Arthritis Clinic

Denver, Colorado, United States, 80230

3

New England Research Associates, LLC

Trumbull, Connecticut, United States, 6611

4

Centre For Rheumatology, Immun. And Arthritis

Fort Lauderdale, Florida, United States, 33334